A market is in motion: innovative molecular diagnostics and therapy are opening up new paths, both in the field of complementary and natural medicine as well as evidence-based medicine. Many diseases which were difficult to treat in the past can now be alleviated, in some cases even with a full remission. The economic perspectives in this sector are also more than promising.
Against this background, Vaccentis is establishing itself as an independent pharmaceutical company with its own basic research and development. The path of a construction and a profitable merger of two high performance participants was paved out in the past. An efficient development of our products through an innovative cooperation and partnership reduces the costs and risks of development and marketing for the future.